All of our locations will be closed Thursday, July 4th, in honor of Independence Day. If you are in need of immediate assistance, please dial 9-1-1. Our clinics will reopen with normal business hours on Friday, July 5th. 

Log in to your appointment

Find Relief
with Spravato

Breakthrough option for Treatment Resistant Depression

Spravato (esketamine)

At The Remedy, Spravato (esketamine) nasal spray represents a significant advancement in our fight against treatment-resistant depression, offering a new avenue for those who have not found relief through traditional treatments.  This therapy is a potential option for adults who have struggled with persistent depressive symptoms despite conventional treatment efforts.

what is spravato?

Spravato is an FDA-approved nasal spray treatment for adults with treatment resistant depression who are taking an antidepressant and still having symptoms of depression and/or suicidal thinking. Taking an antidepressant is a requirement for Spravato therapy. Spravato contains a form of Ketamine called Esketamine that studies have shown to have strong, rapid antidepressant effects.

how does Spravato work?

Spravato works by delivering esKetamine directly into the nasal passage, where it is quickly absorbed into the bloodstream. Spravato (Esketamine) targets glutamate receptors in specific parts of the brain involved in mood regulation and has been shown to relieve symptoms of depression relatively quickly compared to traditional antidepressants.

Approved by the FDA in March 2019, Spravato offers a new hope for individuals who haven’t found success with other depression treatments.

What are the benefits of Spravato?

Who can benefit from Spravato?

Spravato is specifically designed for adults who suffer from major depressive disorder (MDD) and have not responded adequately to traditional antidepressant therapies. It is an option for those seeking alternatives after other treatments have failed.

Please note, Spravato is not suitable for everyone. It is our goal to provide individualized patient-centered care to each person we serve. We will carefully assess each individuals physical, mental, and emotional well-being before recommending Spravato.

Your Path to Healing Starts Here


Consultation with
our expert team


Personalized treatment
plan development


Ongoing support
and monitoring

Your Partner in Recovery

Committed to Your Mental Wellness

At The Remedy, expertise and empathy go hand in hand, providing a supportive environment that mirrors the esteemed care of top academic medical centers. Here, every individual is a partner in their path to wellness, and every treatment is a step toward a brighter, more promising tomorrow.

What Our PAtients Say

“Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.”

– Margret F.

Spravato FAQ

In a clinical study lasting four weeks, Spravato improved symptoms of depression in people taking the drug. One group was given Spravato and an oral antidepressant. The other group was given a placebo (no treatment) and an oral antidepressant. Depression symptoms were measured on a scale of zero to 60 (with higher scores indicating worse depression symptoms). People taking Spravato had fewer depression symptoms than people taking the placebo; their scores improved by 4 points more than scores for people taking the placebo. The greatest symptom improvement was seen in the first 24 hours after people took Spravato. After the four-week trial, some people enrolled in a year-long study. These were people who had a significant improvement in their depression symptoms during the first study. In the year-long study, Spravato also improved depression symptoms. During this study, people were taking an oral antidepressant with either Spravato or a placebo nasal spray. Those who took Spravato were 51% to 70% less likely to relapse back to severe depression than those taking the placebo.

There are no current head-to-head studies comparing the effectiveness of Spravato to IV Ketamine infusions. Based on the experience of practitioners using compounded intranasal ketamine vs. IV Ketamine infusions, Ketamine infusions appear to have a more robust effect in treating depression and can also be individually adjusted to provide the effectiveness you need.

Although it is given as an intranasal spray, the FDA has highly regulated Spravato and requires that the medication either be sent by the pharmacy directly to the practitioner’s office or purchased from the practitioner’s office. The FDA has also required that Spravato be administered in the practitioner’s office with a 2-hour post-application monitoring period in the office.

You can check with your insurance provider as to whether Spravato is a covered service for you, both the medication and application in the office /post-application monitoring period. As it is a brand name drug, as opposed to IV ketamine, which is generic, without insurance, Spravato is quite expensive. However, Janssen, the company that developed Spravato, does have financial support options for patients who need it. Janssen CarePath

The current recommended treatment protocol is for 2x a week of treatment for the 1st 4 weeks, then weekly treatments for weeks 5-9. Thereafter, treatment frequency is once every 1-2 weeks. Currently, there are no studies of Spravato for longer than a year.